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Abstract
Introduction: The aim of this study was to evaluate, under real-life conditions, the safety and efficacy of
tocilizumab in patients having failed anti-TNFa therapy for spondyloarthritis.
Methods: French rheumatologists and internal-medicine practitioners registered on the Club Rhumatismes et
Inflammations website were asked to report on patients given tocilizumab (4 or 8 mg/kg) to treat active disease
meeting Assessment of SpondyloArthritis International Society (ASAS) criteria for axial or peripheral
spondyloarthritis, after anti-TNFa treatment failure. Safety and efficacy after 3 and 6 months were assessed
retrospectively using standardised questionnaires.
Results: Data were obtained for 21 patients, 13 with axial spondyloarthritis (46% men; median age, 42 years;
disease duration, 11 years; HLA-B27-positive, 92.3%) and eight with peripheral spondyloarthritis (25% men; median
age, 40 years; disease duration, 10 years; HLA-B27-positive, 62.5%). No patients with axial disease had at least a 20
mm decrease in the BASDAI, nor a BASDAI50 response or major ASAS-endorsed disease activity score
improvements after 3 or 6 months; an ASAS-endorsed disease activity score clinically important improvement was
noted at month 3 in five of 13 patients and at month 6 in one of four patients. A good DAS28 response was
achieved in four patients with peripheral disease, including one in EULAR remission at month 3. Four patients were
still taking tocilizumab at month 6, including one in EULAR remission and one with a good DAS28 response.
Tocilizumab was well tolerated, with no serious adverse events. Initially elevated acute-phase reactants declined
during tocilizumab therapy.
Conclusion: In patients having failed anti-TNFa therapy, tocilizumab decreased acute-phase reactants but failed to
substantially improve axial spondyloarthritis and was inconsistently effective in peripheral spondyloarthritis.
Introduction
The introduction of TNFa antagonists (anti-TNFa) has
revolutionised the management of patients with spondy-
loarthritis (SpA). Randomised controlled trials demon-
strated substantial efficacy of anti-TNFa therapy in
ankylosing spondylitis (AS) [1-3] and psoriatic arthritis
(PsA) [4-6], with high drug continuation rates [7,8].
Other treatment options are needed, however, for
patients who experience primary or secondary failure of
one or more anti-TNFa agents, as well as for those with
contraindications to anti-TNFa therapy. Preliminary
data suggested that other biologics licensed for rheuma-
toid arthritis (RA), such as rituximab [9,10] and abata-
cept [11-13], might hold promise for AS and PsA, but
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subsequent results in AS or undifferentiated SpA were
disappointing [14-18].
In experimental studies, serum IL-6 levels were ele-
vated in patients with AS and PsA and correlated with
disease activity [19-22]. In addition, IL-6 was expressed
in biopsies of sacroiliac joints from patients with AS,
particularly those with recent-onset disease [23]. IL-6
blockade has been found effective in RA [24], another
chronic inflammatory joint disease. These data suggest
that IL-6 blockade may constitute a therapeutic option
for SpA. One 1996 case report describes a good
response in a patient with severe undifferentiated SpA
given a murine monoclonal anti-IL-6 antibody combined
with a monoclonal anti-CD4 antibody [25]. Since then,
however, the few reports of patients with SpA given the
anti-IL-6 agent tocilizumab indicated mixed effects
[26-29].
Tocilizumab is a humanised monoclonal antibody to
the human IL-6 receptor [30] and is licensed for use in
active RA. Tocilizumab has been used in a few patients
with AS or PsA who had failed treatment with the three
anti-TNFa agents available in France and for whom no
other treatment options existed. Under the auspices of
the Club Rhumatismes et Inflammation (CRI), a section
of the Société Française de Rhumatologie and a partner-
ship with the French Society of Internal Medicine, our
purpose was to evaluate the effectiveness and safety of
tocilizumab therapy in patients with axial or peripheral
SpA having failed anti-TNFa therapy, based on a retro-
spective analysis of data acquired under real-life condi-
tions in France.
Materials and methods
Case ascertainment
All of the 1,400 French rheumatologists and internists
belonging to the CRI were asked, through the CRI web-
site [31], to report cases of active SpA treated with toci-
lizumab in their practice. Three successive monthly
electronic newsletters were sent by email to collect
observations. Reporting occurred from March 2011 to
June 2011. All patients treated with tocilizumab had
given their informed consent to this treatment, and the
study has been approved by a French Institutional
Review Board.
Among reported cases, we selected the patients who
met at least the Assessment of SpondyloArthritis Inter-
national Society (ASAS) criteria for axial SpA [32] or
peripheral SpA [33] and who had active disease at base-
line, defined as a Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) ≥ 40 mm in the axial disease
group and as a Disease Activity Score in 28 joints
(DAS28) > 3.2 in the peripheral disease group. In addi-
tion, analysed patients had to have failed treatment with
at least two anti-TNFa agents and to have received
intravenous tocilizumab infusions in a dosage of 4 or 8
mg/kg every 4 weeks for at least 3 months.
Assessment
For each patient, data were collected by the referent
rheumatologist on a standardised case-report form avail-
able on the CRI website [31]. The following baseline
data were recorded: medical history, former and current
treatments, and disease classification criteria (ASAS
axial SpA [32], ASAS peripheral SpA [33], modified
New York criteria for AS [34], Amor’s criteria [35], Eur-
opean Spondyloarthropathy Study Group criteria [36],
and Classification Criteria for Psoriatic Arthritis [37]).
Efficacy and safety data collected at baseline and at each
tocilizumab infusion were the BASDAI, the Bath Anky-
losing Spondylitis Functional Index (BASFI), the Assess-
ment of SpondyloArthritis International Society-
endorsed disease activity score (ASDAS), the DAS28,
the pain score on a visual analogue scale (VAS), the
patient’s global assessment of disease activity, morning
stiffness duration, tender joint count, swollen joint
count (SJC), the presence of enthesitis or dactylitis,
serum acute-phase reactants (C-reactive protein (CRP)
and erythrocyte sedimentation rate (ESR)), concomitant
treatments, and possible clinical or laboratory adverse
events. Data were collected for the first 3 or 6 months
of tocilizumab therapy.
Data analysis
Completed case-report forms were sent to the coordi-
nating centre (Henri Mondor Teaching Hospital).
Patients meeting the study inclusion criteria were identi-
fied. Missing data on these patients were obtained by
contacting the treatment centres.
Effectiveness was assessed based on data obtained at
baseline (M0), after 3 months (M3), and after 6 months
(M6). Patients with axial disease were classified as
responders if they had at least a 20 mm decrease in the
BASDAI or at least a 50% improvement in the BASDAI
(BASDAI50 response) at M3 or M6, as proposed for
assessment of efficacy of an anti-TNFa drug [38]; sec-
ondary efficacy endpoints were ASDAS major improve-
ment (change by at least 2.0 points), ASDAS clinically
important improvement (change by at least 1.1 points),
percentage change in the VAS pain score, and percen-
tage change in the BASFI. In the group with peripheral
disease, the primary efficacy endpoint was a DAS28
response according to European League Against Rheu-
matism (EULAR) criteria for RA at M3 or M6. Second-
ary efficacy endpoints were the changes in the SJC and
ASDAS, ASDAS major improvement, ASDAS clinically
important improvement, BASDAI improvement, change
in VAS pain score, presence of enthesitis, and corticos-
teroid-sparing effect.
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Safety was assessed based on the rates of adverse
events, serious adverse events, and infections, as well as
on laboratory test results at each tocilizumab infusion.
Results
Baseline characteristics
We identified 21 patients meeting our inclusion criteria,
13 with axial disease and eight with peripheral disease,
according to ASAS classification criteria; one of those
patients has been reported elsewhere [29]. Only one
reported case was not included, because of missing data.
Of the 13 patients with axial disease, nine also met
Amor’s criteria [35] and the European Spondyloarthro-
pathy Study Group criteria [36]; eight of them had
radiographic sacroiliitis and also met the modified New
York criteria for AS [34]. All 13 patients had failed
treatment with the three available anti-TNFa agents
(Table 1 reports the main patient characteristics at base-
line for this group). All 13 patients had morning stiff-
ness of at least 30 minutes’ duration; one patient also
had synovitis at baseline (Patient 8), but suffered mainly
from inflammatory neck and back pain, and thus met
the ASAS classification criteria for axial SpA. Median
age at diagnosis was 42 years (range 26 to 63 years) and
median disease duration was 11 years (range 6 to 27
years). HLA-B27 was present in all the patients but one.
In addition to anti-TNFa agents, five patients had also
failed abatacept therapy and one had failed rituximab
therapy. The tocilizumab dosage was 8 mg/kg in 12
patients and 4 mg/kg in one patient. All 13 patients
Table 1 Main baseline features of the 13 patients meeting ASAS criteria [30] for axial spondyloarthritis
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient
6
Patient 7
Type of SpA AS AS AS AS AS AS AS
Sacroiliitis Grade 4 Grade 4 Grade 3 Grade 4 Grade 3 Grade 3 Grade 4
HLA-B27 + + + + + + +
Gender Female Female Female Male Male Female Male
Disease duration
(years)
9 27 11 6 4 24 19
Main location of
inflammatory
pain
Back, neck, chest,
peripheral enthesitis
(Achilles tendon, knee)
Neck, chest,
peripheral
enthesitisa
Back,
buttock,
chest
Neck Back, neck, buttock Back,
neck,
chest
Back, neck,
peripheral enthesitis
(Achilles tendon)
Concomitant
NSAIDs/steroids
(dosage)
Yes/no Yes/no Yes/no No/no No/no Yes/no Yes/no
Concomitant
DMARDs
No No No Sulfasalazine No No No
Previous
biologics other
than anti-TNF
Abatacept Abatacept Abatacept No No No No
Patient 8 Patient 9 Patient
10
Patient 11 Patient 12 Patient
13
Type of SpA AS and PsA uSpA uSpA uSpA uSpA uSpA
Sacroiliitis Grade 3 Grade 1 Grade 0 Grade 0 Grade 0 Grade 0
HLA-B27 - + + + + +
Gender Male Female Female Male Female Male
Disease duration
(years)
15 11 9 25 6 12
Main location of
inflammatory
pain
Back, neck, arthritis Back, neck,
buttock, chest
Back,
buttock
Back, neck,
buttock
Back, buttock, chest,
peripheral enthesitis
(Achilles tendon)
Back,
neck
Concomitant
NSAIDs/steroids
(dosage)
No/no Yes/no Yes/no No/no Yes/no No/yes
(25 mg/
day)
Concomitant
DMARDs
No No No No No No
Previous
biologics other
than anti-TNF
Rituximab Abatacept Abatacept No No No
AS, ankylosing spondylitis meeting modified New York criteria [33]; ASAS, Assessment of SpondyloArthritis International Society; DMARD, disease-modifying
antirheumatic drug; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis meeting Classification Criteria for Psoriatic Arthritis [36]; SpA,
spondyloarthritis; uSpA, undifferentiated spondyloarthritis. aLocation unknown.
Lekpa et al. Arthritis Research & Therapy 2012, 14:R53
http://arthritis-research.com/content/14/2/R53
Page 3 of 9
were evaluated at M3 (after three tocilizumab infusions);
four patients further continued the treatment and were
also evaluated at M6 (after six tocilizumab infusions).
Of the eight patients with peripheral disease, seven
also met Amor’s criteria or the European Spondyloar-
thropathy Study Group criteria, four met modified New
York criteria for AS, and two met the Classification Cri-
teria for Psoriatic Arthritis. Seven patients had failed
treatment with three anti-TNFa agents, and the remain-
ing patient had failed treatment with two anti-TNFa
agents (Table 2 presents the main patient characteristics
at baseline for this group) One should note that, despite
only one of the patients ha enthesitis, all patients had
peripheral arthritis. Median age at diagnosis was 40
years (range 28 to 63 years) and median disease dura-
tion was 10 years (range 6 to 20 years). Of these eight
patients, five were HLA-B27-positive. One patient had
also failed abatacept therapy and another had failed ana-
kinra therapy. The tocilizumab dosage was 8 mg/kg in
all eight patients. All of the eight peripheral disease
patients were evaluated at M3, and four patients were
also evaluated at M6.
Effectiveness
The effectiveness criteria at M0, M3, and M6 are
reported in Table 3 for the axial disease group and in
Table 4 for the peripheral disease group.
In the group of patients with axial disease, no patient
at M3 had achieved at least a 20 mm decrease in BAS-
DAI, nor a BASDAI50 response (Table 3). Of the 13
patients, five had an ASDAS clinically important
improvement but none had an ASDAS major improve-
ment. The VAS pain score and the BASFI were
unchanged overall. Nevertheless, tocilizumab therapy
was continued for three additional months in four
patients. At M6, none of these four patients had
achieved at least a 20 mm decrease in BASDAI or a
BASDAI50 response, one patient had an ASDAS clini-
cally important improvement, and no patients had an
ASDAS major improvement. A single patient had a 20%
BASFI decrease.
Of the eight patients with AS in the axial disease
group (Patients 1 to 8), none had at least a 20 mm
decrease in BASDAI or a BASDAI50 response at M3,
three had an ASDAS clinically important improvement,
none had an ASDAS major improvement, and only one
patient continued tocilizumab therapy until M6, when
the response was moderate.
Of the five patients (out of the total 21) with a very
high disease activity at baseline according to the ASDAS
(ASDAS > 3.5), four reached an ASDAS clinically
important improvement.
In the group with peripheral disease, the DAS28 at
baseline was ≥ 4 in all eight patients. At M3, four
patients had a good DAS28 response, including one who
met EULAR remission criteria, and another patient had
a moderate DAS28 response. The remaining three
patients had an insufficient response. At last follow-up,
the SJC had decreased in five of the seven patients with
joint swelling at baseline, including two patients who
had no clinical synovitis; in the remaining two patients,
the SJC had increased. At least a 20% SJC decrease was
Table 2 Main baseline features in the eight patients meeting ASAS criteria [32] for peripheral spondyloarthritis
Patient 14 Patient
15
Patient 16 Patient 17 Patient 18 Patient 19 Patient 20 Patient 21
Type of SpA AS AS AS AS uSpA uSpA PsA PsA
Sacroiliitis Grade 2 Grade 3 Grade 3 Grade 3 Grade 0 Grade 1 Grade 0 Grade 0
HLA-B27 + - + + + + - -
Gender Male Female Male Female Female Female Female Female
Disease duration
(years)
8 15 19 6 10 10 10 20
Main articular
and extraarticular
symptoms
Coxitis,
arthritis
Arthritis Arthritis,
uveitis
Peripheral enthesitis (Achilles
tendon, knee, elbow),
arthritis, chest pain
Arthritis Arthritis, IBD,
uveitis
Arthritis,
dactylitis,
psoriasis,
uveitis
Arthritis,
psoriasis
Concomitant
NSAIDs/steroids
(dosage)
Yes/no No/yes
(20 mg/
day)
Yes/yes (5
mg/day)
Yes/yes (15 mg/day) Yes/yes (8
mg/day)
No/yes (10
mg/day)
Yes/yes (20
mg/day)
Yes/yes (20
mg/day)
Concomitant
DMARDs
Methotrexate No Methotrexate Leflunomide Methotrexate Methotrexate Methotrexate Methotrexate
Previous
biologics other
than anti-TNF
No Anakinra No Abatacept No No No No
AS, ankylosing spondylitis meeting modified New York criteria [33]; ASAS, Assessment of SpondyloArthritis International Society; DMARD, disease-modifying
antirheumatic drug; IBD, inflammatory bowel disease; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis meeting Classification Criteria for
Psoriatic Arthritis [36]; SpA, spondyloarthritis; uSpA, undifferentiated spondyloarthritis.
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noted in four patients. The ASDAS was available at M3
for four patients and showed a clinically important
improvement in one patient and a major improvement
in one patient. These two patients were those that had a
very high baseline disease activity according to the
ASDAS (> 3.5). No patient had a BASDAI50 response.
The VAS pain score decreased slightly in two patients
and increased in four patients. Of the four patients trea-
ted for 6 months, two had a good DAS28 response at
M6, including one who was in remission, and two had
an insufficient DAS28 response. The ASDAS was avail-
able at M6 in two patients and showed a clinically
important improvement with no major improvement in
both. At M6, the VAS pain score was increased in three
of four patients and diminished by 0.5 point in one
patient.
Of the eight patients with peripheral disease, seven
were taking glucocorticoid therapy at baseline. The glu-
cocorticoid dosage was increased during tocilizumab
therapy in three patients, left unchanged in two
patients, and decreased in two patients. Two patients
received three and two local corticosteroid injections,
respectively.
Of the four patients with peripheral AS (Patients 14 to
17), two had a good DAS28 response and one had a
moderate DAS 28 response. Neither of the two patients
with PsA (Patients 20 and 21) achieved a clinically rele-
vant improvement.
Acute-phase reactants
Of the seven axial disease patients with CRP elevation at
baseline, six had normal CRP values at M3; the M3 CRP
level was missing in the remaining patient. Similarly, the
ESR decreased substantially in the patients with ESR ele-
vation at baseline (Table 3).
Of the six peripheral disease patients with CRP eleva-
tion at baseline, two patients had normal CRP values at
M3 and four patients at M6. The CRP level had
increased in one patient at M6. The ESR decreased sub-
stantially, except in the patient whose CRP value had
increased by M6.
Safety
No serious adverse events occurred in either group. The
following adverse events were reported: axillary abscess
(Patient 1), toe blister (Patient 1), allergic reaction
Table 3 Baseline and 3-month and 6-month tocilizumab therapy criteria in 13 patients with axial spondyloarthritis
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 Pt 9 Pt 10 Pt 11 Pt 12 Pt 13
BASDAI, 0 to 100
M0 78 90 72 42 77 63 80 48 49 59 48 72 57
M3 (change from M0; %) +6 -19 +1 -15 +1 -1.6 +3.8 -2 +4 -5 +43 -10 -12
M6 (change from M0; %) NA NA NA -17 NA NA NA NA -6 -15 +17 NA NA
ASDAS
M0 4.87 3.35 3.24 3.37 5 5.36 3.8 2.98 2.68 2.41 2.94 3.2 4.12
M3 (change from M0; units) -1.6 -0.8 -0.75 -0.04 -1.5 -1.7 -0.3 -0.24 -1.36 -0.43 -0.35 +0.02 -1.96
M6 (change from M0; units) NA NA NA -1.17 NA NA NA NA -1.02 -0.61 -0.23 NA NA
BASFI, 0 to 100
M0 86 95 63 32 72 MD MD 59.5 50 57 59 28 36
M3 (change from M0; %) -8 -8 +16 +3 +28 MD MD -6 +6 -7 +30 -29 +47
M6 (change from M0; %) NA NA NA +22 NA MD MD NA 0 -7 -34 NA NA
Pain VAS, 0 to 10
M0 9 10 7 4 7 7 8 4 5 6 5 7 4
M3 (change from M0; units) +0.5 -3 +1 0 0 -0.2 +1 +3 +1 -2 0 -1 0
M6 (change from M0; units) NA NA NA -1 NA NA NA NA +1 -2 +2 NA NA
CRP (mg/dl)a
M0 29 0 2 46 35 96 10 10.4 1 1 1.8 3 35.2
M3 (absolute value) 0.3 0 0 NA 3 4 1 < 5 NA NA NA 3 1
M6 (absolute value) NA NA NA 6 NA NA NA NA 0 1 0.6 NA NA
ESR (mm)a
M0 71 9 8 47 35 104 21 12 9 8 1 11 15
M3 (absolute value) 10 2 4 NA 2 2 1 3 NA NA NA 3 1
M6 (absolute value) NA NA NA 5 NA NA NA NA 4 1 1 NA NA
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Assessment of SpondyloArthritis International Society-endorsed disease activity score; BASFI,
Bath Ankylosing Spondylitis Functional Index; VAS, visual analogue scale; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; M0, month 0 (baseline); M3,
month 3; M6, month 6; MD, missing data; NA, not available; Pt, Patient. aFor CRP and ESR, the table shows only the values at baseline (M0) and at last follow-up
(M3 or M6).
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Table 4 Baseline and 3-month and 6-month tocilizumab therapy evaluation criteria in eight patients with peripheral
spondyloarthritis
Patient 14 Patient 15 Patient 16 Patient 17 Patient 18 Patient 19 Patient 20 Patient 21
DAS28
M0 4.02 4.52 5 4.58 5.41 6.2 5.23 4.92
M3 (absolute value) 2.82 3.85 4.3 2.88 3.18 1.1 5.1 4.70
M3 EULAR response (yes/no) Yes (good) No Yes (moderate) Yes (good) Yes (good) Yes (remission) No No
M6 (absolute value) 1.95 4.01 5.34 3.12 NA NA NA NA
M6 EULAR response (yes/no) Yes (remission) No No Yes (good) NA NA NA NA
ASDAS
M0 2.41 4.03 MD MD MD 3.8 3 MD
M3 (absolute value) 1.50 2.64 MD MD MD 1.35 3.1 MD
M6 (absolute value) 1.03 2.79 MD MD MD NA NA MD
SJCa
M0 7 2 2 0 3 9 4 7
M3 (absolute value) NA NA NA NA 7 0 3 6
M6 (absolute value) 0 6 1 0 NA NA NA NA
TJCa
M0 7 6 5 5 0 15 7 12
M3 (absolute value) NA NA NA NA 0 0 6 11
M6 (absolute value) 2 4 3 8 NA NA NA NA
BASDAI, 0 to 100
M0 42 75 NA 79.4 67 48 4.7 NA
M3 (change from M0; %) -31 -6.7 NA -9 +6 NA -2.1 NA
M6 (change from M0; %) -59.5 -4.7 NA -32 NA NA NA NA
BASFI, 0 to 100
M0 40 72 MD MD 54 70 NA NA
M3 (change from M0, %) -17.5 -26 MD MD +44 NA NA NA
M6 (change from M0, %) -12.5 -12.5 MD MD NA NA NA NA
Pain VAS, 0 to 10
M0 1.5 7 5 7 7 5 6 8
M3 (absolute value) 2 8 NA 6 8 1 6.5 6
M6 (absolute value) 1 9 6 7.5 NA NA NA NA
PGA, 0 to 10
M0 1 6 7 7.5 7 5.2 6.5 8
M3 (absolute value) 3.5 6 MD MD 7 1 6.5 8
M6 (absolute value) 1.2 6 8 MD NA NA NA NA
CRP (mg/dl)a
M0 20.2 17 119 12 112.3 65 4 1
M3 (absolute value) NA NA NA NA 9.5 1 5 1
M6 (absolute value) 0.4 0.8 128 1 NA NA NA NA
ESR (mm)a
M0 39 22 67 26 103 60 27 7
M3 (absolute value) NA NA NA NA 8 4 7 8
M6 (absolute value) 5 7 70 2 NA NA NA NA
ASDAS, Assessment of SpondyloArthritis International Society endorsed disease activity score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI,
Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; EULAR,
European League Against Rheumatism; M0, month 0 (baseline); M3, month 3; M6, month 6; NA, not available; MD, missing data; PGA, patient’s global assessment
of disease activity; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale. aFor SJC, TJC, CRP, and ESR, the table shows only the values at
baseline (M0) and at last follow-up (M3 or M6).
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(Patient 2), oral ulcers (Patients 14 and 17), nasopharyn-
gitis (Patient 15), Q fever (Patient 16), vasospasm of the
extremities (Patient 17), liver enzyme elevation < 3N
(Patient 8), and cholesterol and triglyceride elevation
(Patient 8).
Flares of anterior uveitis occurred in two patients
(Patients 7 and 16) with previous episodes of uveitis,
and de novo acute anterior uveitis occurred in one
patient (Patient 5). A flare of psoriasis also occurred in
Patient 16, who had a previous history of psoriasis.
Discussion
We obtained detailed descriptions of 3-month and 6-
month outcomes of tocilizumab therapy in 21 patients
with SpA who had failed anti-TNFa therapy. In the 13
patients meeting the ASAS criteria for axial SpA [32],
tocilizumab therapy produced no significant improve-
ment based on BASDAI variation or ASDAS major
improvement at M3 (n = 13) or M6 (n = 4). An ASDAS
clinically important improvement was achieved in five
patients at M3 and in one patient at M6. In the eight
patients meeting the ASAS criteria for peripheral SpA
[33], the effects of tocilizumab therapy were mixed: at
M3, four patients had a good DAS28 response, including
one in EULAR remission; and four patients were still
receiving tocilizumab at M6, including one in EULAR
remission and one with a good DAS28 response. Glob-
ally, tocilizumab was safe in both groups, with few
adverse events and no serious adverse events.
Tocilizumab provided no clinically relevant effects in
the patients with axial disease. The effects were mixed in
the group with peripheral disease. Tocilizumab was inef-
fective in both the patients with axial AS and in those
with axial undifferentiated SpA. The numbers of patients
with peripheral SpA were too small for subgroup analyses
by diagnosis; however, the good M6 response in the two
patients with peripheral AS is worth noting.
We found four previous case reports of tocilizumab
therapy for SpA published in 2009 and 2010 [26-29].
The effects in these reports were mixed, in keeping with
our findings. In the two patients with peripheral SpA,
tocilizumab induced clinical improvements [26,27]. The
other two patients had axial SpA; among these, one
patient benefited clinically but had no improvements in
spinal magnetic resonance imaging findings after 18
weeks [28], and the other had no clinical improvements
[29]. Two preliminary reports in groups of patients have
been published: one was a study of 18 patients with
axial disease given tocilizumab for a median of 6.5
months, which showed improvements in a single patient
[39]; the other study showed no meaningful clinical
effects after three to six tocilizumab infusions in five
patients with axial SpA [40]. Taken together, our study
findings and previously published data fail to indicate
substantial effectiveness of tocilizumab in axial SpA
refractory to anti-TNFa therapy and suggest limited
effectiveness in peripheral forms. These results may
seem surprising, given the available evidence that IL-6
plays a significant pathogenic role in SpA [19-23]. In an
animal model of TNF-mediated bilateral sacroiliitis,
however, IL-6 was not a crucial regulator of the disease
process [41]. These findings point to substantial differ-
ences in the mechanisms underlying RA and SpA,
which translate into differences in the effectiveness of
pharmacotherapeutic agents. Several other drugs known
to be effective in RA have also failed to improve patients
with SpA, including methotrexate, rituximab [14-16],
abatacept [17,18], and anakinra [42-44].
The absence of meaningful clinical improvements in
our study contrasted with decreases in acute-phase reac-
tants during tocilizumab therapy. These decreases indi-
cate that IL-6 blockade was effective in our patients. Our
results demonstrate that the markers for systemic inflam-
mation can return to normal despite no clinical improve-
ment. Consequently, ESR and CRP values cannot be used
as isolated surrogate markers for efficacy in SpA patients,
even for those with elevated ESR and CRP values at base-
line. On the other hand, incorporating ESR or CRP into
composite scores such as the ASDAS can improve the
assessment of patients with SpA, and perhaps improve
the selection of candidate patients for other biologics
after several failures. In line with this hypothesis we can
note that, within axial patients with a very high disease
activity at baseline according to the ASDAS (ASDAS >
3.5), we observed four out of five (80%) patients with an
ASDAS clinically important improvement.
Our study has several limitations. Firstly, we should
highlight the retrospective design and the limited num-
ber of patients. Our purpose was not to conduct a ther-
apeutic trial, however, but instead was to learn from the
patients who had been treated under real-life conditions
in France. Case ascertainment was incomplete, because
not all rheumatologists and internists in France belong
to the CRI; on the other hand, those who do belong to
the CRI are used to providing detailed case reports -
indeed, we excluded only one case because of missing
data. We selected patients fulfilling recent ASAS criteria
for axial SpA [32] or for peripheral SpA [33], and we
analysed these two groups separately because they are
clearly distinguished by the criteria.
Secondly, BASDAI alone is not specific enough to eval-
uate the inflammatory activity of axial SpA in these
highly refractory patients. However, the BASDAI and
expert opinion are the criteria recommended in France
to start biologics after failure of non steroidal anti-
inflammatory drugs. There is clearly a need to find new,
more stringent, criteria for refractory patients failing
treatment with at least two biologics. The ASDAS is a
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good candidate for these new criteria. It should be argued
that some of our patients might actually have other
causes of back pain than SpA; however, they all had sig-
nificant morning stiffness and more than one-half of the
axial patients had an increased baseline CRP level, sug-
gesting that SpA itself was still active in those patients. In
addition, doses and methods of administration of tocili-
zumab are those used in RA, a disease with different
pathogenesis. Further therapeutic approaches different
from those used for RA are needed, reaching as far as
research on the new pathogenesis hypothesis in SpA.
Conclusion
Despite a significant decrease of acute-phase reactants,
IL-6 blockade did not improve the clinical status of
patients with axial SpA who had previously failed anti-
TNFa therapy. Tocilizumab does not seem to hold pro-
mise for the management of axial SpA refractory to anti-
TNFa agents, although only the ongoing randomised
controlled trials with this drug in AS could confirm this
supposition. There is a need for studies of other drugs
[45], different from those used in RA, as well as for conti-
nuing research into the pathogenesis of SpA.
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